BMS-955176

BMS-955176 is an experimental second generation HIV maturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.[1] First generation maturation inhibitors such as bevirimat were ineffective against some naturally occurring changes (polymorphisms) in the Gag protease polyprotein; BMS-955176 has been selected to better tolerate gag polymorphisms.[2][3]

BMS-955176
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
UNII
Chemical and physical data
FormulaC42H62N2O4S
Molar mass691.03 g·mol−1
3D model (JSmol)

Studies

Results of a phase 2a trial of BMS-955176 was reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI).[4] Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms.[4][5] Phase 2b studies are currently ongoing in early 2016.[6][7] It appears that development of BMS-955176 has been terminated.[8]

gollark: If you just send someone a grid of pixels, they might display them in a different way to you.
gollark: I'm not sure why you would decide to be made of antimatter. That would be silly.
gollark: https://en.wikipedia.org/wiki/CP_violation
gollark: I assume you have particle accelerators.
gollark: Well, the obvious approach is to use the weird asymmetric things in particle physics which I recall existing.

References
  1. "BMS Maturation Inhibitor Is Potent Against HIV in Early Trial". 25 February 2015. Archived from the original on 23 July 2015. Retrieved 22 July 2015.
  2. "CROI2015: New HIV maturation inhibitor BMS-955176 appears more potent than earlier beviramat - Project Inform".
  3. Wang D, Lu W, Li F (November 2015). "Pharmacological intervention of HIV-1 maturation". Acta Pharmaceutica Sinica. B. 5 (6): 493–9. doi:10.1016/j.apsb.2015.05.004. PMC 4675807. PMID 26713265.
  4. "Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor | CROI Conference". www.croiconference.org. Retrieved 2016-01-01.
  5. "HIV maturation inhibitor BMS-955176 looks promising in early study". www.aidsmap.com. Retrieved 2016-01-01.
  6. "Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2016-01-01.
  7. Clinical trial number NCT02386098 for "Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults" at ClinicalTrials.gov
  8. "GSK Discontinues Development of Maturation Inhibitor BMS-955176".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.